|
For Indian pharma, technology plays a pivotal role in driving innovation, efficiency, and competitiveness. One indisputable technology with the potential to revolutionize drug discovery and development in India is artificial intelligence (AI). Now AI, with its machine learning algorithms, can analyse vast datasets, identify patterns, and predict outcomes, significantly accelerating the drug discovery process.
Dr Venkat Mattela, CEO and founder, Ceremorphic Life Sciences, said that high-performance computing, another technological frontier, enables simulations and modelling, reducing the time and cost involved in identifying potential drug candidates.
In addition to AI and high-performance computing, the Internet of Things (IoT) is emerging as a valuable asset in pharmaceutical manufacturing. IoT devices can monitor and optimize various aspects of the manufacturing process, ensuring quality control and efficiency. For India, a country known for its generic drug production, these technologies can enhance the reputation of Indian pharmaceuticals by ensuring consistency and adherence to global quality standards, he added.
In India, where a large population presents diverse genetic variations, AI can help tailor medications to specific genetic profiles, making treatments more effective. AI is an approximate technology, meaning it can reduce the problem dimension but cannot give an exact answer; this is crucial to achieving the eventual goal of drug research with zero side effects and personalized medicine. These expectations are big and perceived as unachievable with the current expertise and technology available, said Dr Mattela.
One major obstacle is the need for substantial investments in research and development. Many Indian pharmaceutical companies, especially smaller ones, may struggle to allocate resources for exploring and adopting advanced technologies. Bridging this financial gap requires collaborative efforts between the government, private sector, and research institutions to create a conducive environment for innovation, he noted.
Regulatory hurdles also pose a challenge during the integration of advanced technologies. India's pharmaceutical sector operates within a complex regulatory framework, and adapting regulations to accommodate emerging technologies is a gradual process. Striking a balance between fostering innovation and ensuring safety and efficacy is crucial. The government needs to work closely with industry experts to develop guidelines that encourage the adoption of technology while maintaining high standards of quality and safety, said Dr Mattela.
Despite these challenges, some strides have been made in integrating technology into the Indian pharmaceutical landscape. Drug discovery, a traditionally time-consuming and costly process, has witnessed notable advancements. This is where high-performance computing decreases expenses in identifying potential drug candidates.
As the Indian pharma industry navigates these challenges, the integration of these emerging technologies will not only strengthen India's position in the global pharmaceutical market but also contribute to the advancement of healthcare on a global scale. Local and global partnerships will facilitate knowledge transfer, access to advanced technologies, and joint research initiatives. “We see the Ceremorphic Life Sciences platform, BioCompDiscoverX as one such first solution for the India that is capable of bringing efficiency at each level of the current design pipeline with a focus currently on oncology and neurology. It aims to leverage the strength of AI-driven expertise, analog and quantum technologies, said Dr Mattela.
|